FE Healthcare

🔬 New Blood Test Could Predict Weight Loss Impact on Blood Sugar! 🌡️ A breakthrough study from the University of Sydney has discovered that measuring specific fats in blood serum may help predict whether weight loss will improve blood sugar levels in pre-diabetic patients. This insight could lead to more personalised treatment plans for diabetes prevention! Key Findings: 🔹 Certain fats, like sphingolipids, predict changes in fasting plasma glucose. 🔹 Different fats in the blood are linked to changes in HbA1c, insulin, and insulin resistance. 🔹 Over half of pre-diabetic patients do not achieve normal blood sugar levels after weight loss. 🔹 This test could be a game-changer in diabetes prevention and personalised treatment plans. #Healthcare #FEHealthcare #DiabetesPrevention #BloodTest #PersonalisedMedicine #HealthInnovation #DiabetesManagement #Wellness #AIinHealthcare #PreDiabetes #HealthResearch #WeightLossJourney #BloodSugarControl #HealthyLiving Sakshi Kuchroo | Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

#FEHealthAlert #Hairfall 💡 Struggling with hair fall? Don't ignore the early signs of alopecia. 🌿 Early intervention is crucial to managing hair loss effectively. Most people delay seeking professional help, relying on DIY remedies that often don't address the root cause. Alopecia is a complex condition, and only a healthcare professional can diagnose and recommend appropriate treatments. Key early signs to watch out for: 🔹 Gradual thinning on the top of the head 🔹 Circular or patchy bald spots 🔹 Sudden hair loosening 🔹 Full-body hair loss 🔹 Patches of scaling over the scalp 📋 Remember: Consulting a doctor early can make a significant difference in preserving your hair. 🙌 #Healthcare #FEHealthcare #AlopeciaCare #HairLossPrevention #HairHealth #HealthTips #Dermatology #HairCareSolutions #Wellness #SkinAndHairCare #PreventHairLoss #HealthyLiving #SelfCare Dr. Stuti Khare Shukla | Dr N Rekha Singh | Dr Debraj Shome | Sushmita Panda | Sakshi Kuchroo | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

#FEHealthInsights 🌞 Is Vitamin D Deficiency Behind Your Persistent Headaches? 🌞 Did you know that a lack of vitamin D could be triggering your frequent headaches? Vitamin D plays a crucial role in reducing nitric oxide production, which acts as a mediator for migraines. Low levels of this essential nutrient may also impact serotonin, leading to migraine episodes. 🧠💊 🔍 Key Insights • 🧬 Vitamin D deficiency linked to headaches and migraines • 🌿 Reduces nitric oxide synthesis, which triggers migraines • 💡 Boost your Vitamin D with sunlight, diet, and supplements • 🩺 Consult a doctor for personalized advice on your Vitamin D needs #HealthcareI #FEHealthcareI #VitaminD #HeadacheRelief #MigrainePrevention #HealthTips 🌞 #VitaminDDeficiency #BrainHealth #Wellness Sakshi Kuchroo | Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

#FEHealthAlet 🌍 World Health Organization Launches Global Framework to Investigate the Origins of Pathogens 🌍 The WHO has introduced a vital global framework aimed at investigating the origins of new and re-emerging pathogens. This revolutionary resource is designed for scientists, researchers, and public health authorities to effectively trace outbreaks and prevent future pandemics, safeguarding human and animal health globally. 🧬🔬 🔍 Key Highlights 📊 A structured "how-to" guide for investigating pathogens 🧑🔬 Focus on early investigations, human-animal interface studies, and genomics 🌐 Aligns with International Health Regulations (IHR) 🛡️ Aims to prevent future pandemics by swiftly identifying outbreak sources #HealthcareI #FEHealthcareI #GlobalHealth 🌍 #PandemicPrevention #PathogenResearch #OneHealth 🌿 #WHO #PublicHealth #HealthSecurity #Biosafety #Epidemics Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🌍 71% Spike in Cholera Deaths Globally - Urgent Action Needed! 🌍 Cholera continues to ravage vulnerable communities, with a 71% increase in deaths and 13% rise in reported cases globally in 2023, according to the WHO. Countries like Afghanistan, DR Congo, Malawi, and Somalia are reporting over 10,000 cases, and cholera outbreaks are still active in 22 countries as of 2024. 🚨 The alarming rise calls for immediate efforts to improve access to treatment, clean water, and sanitation. Despite low vaccine stock, 35 million doses were shipped last year using a single-dose strategy. Let's unite to fight this preventable disease and bring relief to affected communities! 🔍 Key Highlights • 71% increase in cholera deaths in 2023 • 22 countries currently battling active outbreaks • Cholera continues to disproportionately affect children under five • Urgent need for access to vaccines, diagnostics, and essential treatments #HealthcareI #FEHealthcareI #CholeraCrisis #PublicHealth #GlobalHealth #DiseasePrevention #Vaccines #HealthEquity #FightCholera #WHO #HealthResponse #SanitationMatters Sushmita Panda | Sakshi Kuchroo | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🌟 Entod Pharmaceuticals Achieves Milestone with DCGI Approval for PresVu Eye Drops! 👁️✨ Entod Pharmaceuticals has announced that it has received final approval from the Drug Controller General (India) (DCGI) for its revolutionary PresVu eye drops, designed to reduce dependency on reading glasses for those affected by presbyopia. This marks a significant step in advancing eye care in India and globally. Key Highlights: 👓 First in India: PresVu is the first eye drop in India specifically formulated for presbyopia, a common age-related vision condition. 🔬 Advanced Technology: Utilizes dynamic buffer technology for consistent efficacy and safety over extended use. 🌍 Global Impact: Presbyopia affects over a billion people worldwide, impacting daily life and productivity. 🇮🇳 Make in India: Aligns with the ‘Make In India’ initiative, offering advanced and affordable treatments. #Healthcare #FEHealthtips #FEHealthcare #EyeCare #Innovation #Pharmaceuticals #MakeInIndia #VisionHealth #MedicalAdvancements #Aging #Productivity #PatientCare #Ophthalmology Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🌟 Unlocking the Secrets of Ultra-Short Sleep! 🛌✨ Daisuke Hori, a Japanese entrepreneur, has stunned the world with his claim of sleeping just 30 minutes a day for the past 12 years, boosting his productivity to new heights. Discover how Hori’s unconventional sleep routine is challenging the norms and inspiring a new wave of ultra-short sleepers. Key Highlights: 🕒 12-Year Journey: Reduced sleep to 30 minutes daily, improving work efficiency. 🏋️♂️ Active Lifestyle: Stays energetic with regular exercise and coffee routines. 🎓 Teaching Others: Trained 2,100+ students to adopt ultra-short sleep patterns. #Healthcare #FEHealthtips #FEHealthcare #Sleep #Productivity #Wellness #HealthyLiving #Innovation #MentalHealth #WorkLifeBalance #Inspiration #SleepOptimization #HealthCommunity Sushmita Panda | Sakshi Kuchroo | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🚀 AUROBINDO PHARMA LTD Pharma Accelerates Growth with Strategic Investments in R&D and Capacity Expansion! 💊 Aurobindo Pharma, a leading player in the pharmaceutical industry, is on a rapid growth trajectory, focusing on enhancing self-reliance and expanding its global footprint. With significant investments in R&D and new manufacturing capacities, the company is well-positioned to capitalize on emerging market opportunities. 🔬 Key Highlights: 📈 Strategic Expansion: Investing ₹2,500 Crore in a Penicillin-G plant under the PLI scheme. 🧪 R&D Focus: Development of 14 biosimilar products and 14 peptide API DMFs submitted in the US. 🌏 Global Reach: Entered the Indonesian market, acquiring 17 brands and expanding operations. 🏭 Capacity Growth: Building a biologics manufacturing plant with a capacity of 25-30 million vials per annum. 💰 Financial Strength: Announced a share buyback scheme of ₹750 Crore. With its robust pipeline and continued focus on innovation, Aurobindo Pharma is set to achieve sustainable top-line and bottom-line growth, driving better healthcare outcomes worldwide. #Healthcare #FEHealthtips #FEHealthcare #AurobindoPharma #Pharmaceuticals #R&D #GrowthStrategy #Biosimilars #GlobalExpansion #Innovation #HealthcareExcellence Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🚀 MANKIND PHARMA LTD Enters the Topical Analgesic Market with Nimulid Strong! 💪 Mankind Pharma has made a strategic move into the topical analgesic market by launching Nimulid Strong—a powerful solution targeting neck pain, available in both gel and spray variants. With 2X diclofenac concentration, this innovative product promises faster relief, empowering millions to live more freely. 🎥 Accompanied by the #GardanHilaateRaho campaign, Mankind Pharma is positioning itself as a leader in pain management. With the Indian topical analgesic market valued at ₹1488 crore, this launch is perfectly timed to capture a significant share. Key Highlights: 💡 Revolutionary 2X diclofenac formulation. 🎯 Focus on specific neck pain relief. 📈 Aligns with Mankind Pharma’s commitment to affordable healthcare. 📺 Comprehensive marketing campaign across various platforms. #Healthcare #FEHealthtips #FEHealthcare #MankindPharma #PainRelief #TopicalAnalgesic #NimulidStrong #GardanHilaateRaho #Pharmaceuticals #HealthInnovation #PainManagement Ramesh Juneja | Rajeev Juneja | Sheetal Arora | Arjun Juneja | Sushmita Panda | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)

🌟 Sanofi’s MS Drug Faces Mixed Results in Late-Stage Trials 🌟 Sanofi’s most advanced multiple sclerosis (MS) drug candidate, Tolebrutinib, has shown a mixed performance in late-stage trials. While it did not outperform the existing drug Aubagio in treating the common relapsing form of MS, it did show promise in treating the less common progressive form by slowing disability progression. 🧬 💡 Key Highlights: 🔬 Trial Results: Tolebrutinib failed to reduce relapse rates in common relapsing MS but succeeded in slowing disability progression in progressive MS. 📈 Market Impact: Despite the mixed results, shares rose, reflecting investor confidence in the drug's potential. 📅 Next Steps: Sanofi aims to file for regulatory approval by the end of 2024, positioning Tolebrutinib as a potential breakthrough in MS treatment. 🔍 Stay tuned for more updates as Sanofi presents detailed findings at the upcoming medical conference in Copenhagen on September 20. #Healthcare #FEHealthtips #FEHealthcare #MultipleSclerosis #Sanofi #PharmaNews #DrugDevelopment #MSResearch #ClinicalTrials #Biotech #MedicalResearch Paul Hudson | Jean-Baptiste de Chatillon | Thomas Triomphe | Bill Sibold | Olivier Charmeil | John Reed | Natalie Bickford | Julie Van Ongevalle | Madeleine Roach | Sushmita Panda | Sakshi Kuchroo | Sumana Sarkar | E Kumar Sharma | Roshun Povaiah | Financial Express (India)